miR-22-3p/PGC1通过PPAR抑制乳腺癌细胞的肿瘤发生。
miR-22-3p/PGC1 Suppresses Breast Cancer Cell Tumorigenesis via PPAR.
作者信息
Wang Xuehui, Yao Zhilu, Fang Lin
机构信息
Department of Thyroid and Breast Surgery, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai 200072, China.
Nanjing Medical University, Nanjing 211166, China.
出版信息
PPAR Res. 2021 Mar 12;2021:6661828. doi: 10.1155/2021/6661828. eCollection 2021.
In this study, we found that miR-22-3p expression was decreased in breast cancer (BC) cell lines and tissues. Overexpression of miR-22-3p inhibited the proliferation and migration of BC cells in vitro and in vivo, while depletion of miR-22-3p exhibited the opposite effect. Importantly, miR-22-3p could directly target PGC1 and finally regulate the PPAR pathway in BC. In conclusion, miR-22-3p/PGC1 suppresses BC cell tumorigenesis via PPAR, which may become a potential biomarker and therapeutic target.
在本研究中，我们发现miR-22-3p在乳腺癌（BC）细胞系和组织中的表达降低。miR-22-3p的过表达在体外和体内均抑制了BC细胞的增殖和迁移，而miR-22-3p的缺失则表现出相反的效果。重要的是，miR-22-3p可直接靶向PGC1并最终调节BC中的PPAR通路。总之，miR-22-3p/PGC1通过PPAR抑制BC细胞的肿瘤发生，这可能成为一种潜在的生物标志物和治疗靶点。
Zotero 插件